REG - Redx Pharma plc - Board Committee Changes

Redx PharmaAnnouncement

09/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI0723Ea&default-theme=true

RNS Number : 0723E  Redx Pharma plc  09 March 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Board Committee Changes

 

Establishment of Science Committee to Review and Assess Redx's R&D
Programs and Strategy

 

Alderley Park, 9 March 2022 Redx (AIM: REDX), the clinical-stage biotechnology
company focused on discovering and developing novel, small molecule, highly
targeted therapeutics for the treatment of cancer and fibrotic disease,
announces that its Board of Directors has established a Science Committee.

 

The Science Committee will be responsible for reviewing and assessing Redx's
R&D programs and strategies, in addition to overseeing the Company's
progress in achieving its R&D goals and objectives. The new Committee will
be chaired by Dr Bernhard Kirschbaum, a longstanding member of the Board with
over 25 years of experience in pharmaceutical research and drug development.
The Committee will also consist of Chief Executive Officer, Lisa Anson and
Non-Executive Director, Dr Rob Scott as members.

 

As a result of his new responsibilities, Dr Kirschbaum will step down from his
role as Chair of the Remuneration Committee, but will remain a member of this
committee. The Board has appointed Sarah Gordon Wild as the new Chair of the
Remuneration Committee. Sarah has extensive experience in the biotechnology
sector and capital markets, including over 20 years as a senior
biotechnology/healthcare analyst on Wall Street. Dr Kirschbaum will also step
down from his role as a committee member on the Audit Committee, and will be
replaced by Dr Rob Scott. The changes are all effective immediately.

 

Dr Jane Griffiths, Chair of the Board of Redx, commented: "The creation of a
new Science Committee reflects the strong progress made in Redx's pipeline
over the past year, with two wholly-owned assets now in the clinic. The Board
and I look forward to further cementing Redx's position as a successful
clinical-stage biotech company and progressing the Company's drug candidates
through the clinical development process."

 

 For further information, please contact:

 Redx Pharma Plc                                 T: +44 (0)1625 469 918

 ir@redxpharma.com (mailto:IR@redxpharma.com)

 UK Headquarters

 Dr Jane Griffiths, Chair
 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)     T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                  T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)      T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                  T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Initial results were reported
in October 2021, with full Phase 1 results expected in 2022.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting
fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which
AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEALDPELPAEFA